Viking Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Viking Therapeutics'in kazancının yıllık 8.1% oranında azalması, yıllık gelirinin ise yıllık 79.7% oranında artması beklenmektedir. EPS'nin düşmesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -23% olacağı tahmin edilmektedir.

Anahtar bilgiler

-8.1%

Kazanç büyüme oranı

-4.7%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.6%
Gelir büyüme oranı	79.7%
Gelecekteki özkaynak getirisi	-23.0%
Analist kapsamı	Good
Son güncelleme	20 Dec 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow

Dec 23

Viking Therapeutics: Holiday Gift

Dec 19

Viking Stock Pops, Then Drops On Latest Obesity/MASH Data: Why I'm Still Bullish

Dec 05

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Nov 04

Viking Therapeutics: Lots Of Positives

Oct 28

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Sep 25

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Sep 07

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Aug 30

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Jul 25

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Apr 26

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Jun 07

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Mar 05

Viking Therapeutics: Playing Second Fiddle To Madrigal

Aug 30

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Jul 13

Revisiting Viking Therapeutics

Apr 20

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Apr 12

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Dec 17

Viking Therapeutics: Remaining Bullish And Sticking To My Plan

Aug 27

Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder

Jun 17

Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Jan 13

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:VKTX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	25	-209	-252	-223	12
12/31/2025	2	-167	-196	-156	13
12/31/2024	N/A	-107	-114	-90	14
9/30/2024	N/A	-99	-74	-74	N/A
6/30/2024	N/A	-97	-72	-72	N/A
3/31/2024	N/A	-94	-55	-55	N/A
12/31/2023	N/A	-86	-73	-73	N/A
9/30/2023	N/A	-81	-67	-67	N/A
6/30/2023	N/A	-74	-61	-61	N/A
3/31/2023	N/A	-72	-63	-63	N/A
12/31/2022	N/A	-69	-48	-48	N/A
9/30/2022	N/A	-62	-50	-50	N/A
6/30/2022	N/A	-59	-47	-47	N/A
3/31/2022	N/A	-57	-47	-47	N/A
12/31/2021	N/A	-55	-48	-48	N/A
9/30/2021	N/A	-54	-41	-41	N/A
6/30/2021	N/A	-50	-35	-35	N/A
3/31/2021	N/A	-44	-28	-28	N/A
12/31/2020	N/A	-39	-22	-22	N/A
9/30/2020	N/A	-36	-28	-28	N/A
6/30/2020	N/A	-32	-26	-26	N/A
3/31/2020	N/A	-31	-26	-26	N/A
12/31/2019	N/A	-26	-25	-25	N/A
9/30/2019	N/A	-24	-16	-16	N/A
6/30/2019	N/A	-24	-18	-18	N/A
3/31/2019	N/A	-23	-17	-17	N/A
12/31/2018	N/A	-22	-19	-19	N/A
9/30/2018	N/A	-21	-20	-20	N/A
6/30/2018	N/A	-20	N/A	-18	N/A
3/31/2018	N/A	-19	N/A	-17	N/A
12/31/2017	N/A	-21	N/A	-15	N/A
9/30/2017	N/A	-20	N/A	-13	N/A
6/30/2017	N/A	-18	N/A	-13	N/A
3/31/2017	N/A	-16	N/A	-12	N/A
12/31/2016	N/A	-15	N/A	-11	N/A
9/30/2016	N/A	-16	N/A	-12	N/A
6/30/2016	N/A	-17	N/A	-13	N/A
3/31/2016	N/A	-21	N/A	-11	N/A
12/31/2015	N/A	-23	N/A	-9	N/A
9/30/2015	N/A	-17	N/A	-6	N/A
6/30/2015	N/A	-12	N/A	-3	N/A
3/31/2015	N/A	-27	N/A	-2	N/A
12/31/2014	N/A	-22	N/A	-2	N/A
9/30/2014	N/A	-23	N/A	-1	N/A
6/30/2014	N/A	-23	N/A	-1	N/A
3/31/2014	N/A	0	N/A	0	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: VKTX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: VKTX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: VKTX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: VKTX şirketinin gelirinin (yıllık 79.7% ) US pazarından (yıllık 9.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: VKTX şirketinin gelirinin (yıllık 79.7% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: VKTX 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/26 18:29
Gün Sonu Hisse Fiyatı	2024/12/26 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Viking Therapeutics, Inc. 25 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Matthew Luchini	BMO Capital Markets Equity Research
Mayank Mamtani	B. Riley Securities, Inc.
Julian Harrison	BTIG

Viking Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 14% to US$108

Price target increased by 11% to US$40.89

Price target increased by 8.8% to US$37.00

Price target increased by 9.1% to US$36.33

Price target increased by 7.5% to US$31.50

Price target increased by 12% to US$30.80

Recent updates

We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow

Viking Therapeutics: Holiday Gift

Viking Stock Pops, Then Drops On Latest Obesity/MASH Data: Why I'm Still Bullish

New major risk - Revenue and earnings growth

Viking Therapeutics, Inc. Presents Results from Phase 2b VOYage Study of VOYage Study of Voyage Study of Voyage

New major risk - Revenue and earnings growth

Viking Therapeutics, Inc. Announces Reports New Data from VK2735 Obesity Program at ObesityWeek 2024

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Viking Therapeutics to Highlight Clinical Data from VENTURE Phase 2 Study of Subcutaneous Vv2735 in Obese Patients and Phase 1 Trial of Oral Vv2735 in Healthy Subjects to Be Presented

Viking Therapeutics: Lots Of Positives

Independent Director exercised options and sold US$1.2m worth of stock

Viking Therapeutics, Inc. to Report Q3, 2024 Results on Oct 23, 2024

Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

President notifies of intention to sell stock

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Independent Director exercised options and sold US$1.0m worth of stock

President recently sold US$6.7m worth of stock

President notifies of intention to sell stock

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Viking Therapeutics, Inc. to Report Q2, 2024 Results on Jul 24, 2024

Viking Therapeutics, Inc. Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists At 84th Scientific Sessions of the American Diabetes Association

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2B Voyage Study of Vk2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (Nash)

New major risk - Revenue and earnings growth

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Viking Therapeutics, Inc. to Report Q1, 2024 Results on Apr 24, 2024

Viking Therapeutics, Inc., Annual General Meeting, May 21, 2024

Viking Therapeutics: Future Weight Loss Heavyweight?

Price target increased by 14% to US$108

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Viking Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $550.035 million.

Viking Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

New major risk - Share price stability

Price target increased by 11% to US$40.89

Price target increased by 8.8% to US$37.00

President notifies of intention to sell stock

Price target increased by 9.1% to US$36.33

New major risk - Revenue and earnings growth

Viking Therapeutics, Inc. to Report Q4, 2023 Results on Feb 07, 2024

President notifies of intention to sell stock

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

Chief Financial Officer recently sold US$269k worth of stock

Chief Financial Officer notifies of intention to sell stock

New minor risk - Share price stability

Viking Therapeutics, Inc. Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting 2023

Viking Therapeutics, Inc. to Report Q3, 2023 Results on Oct 25, 2023

Viking Therapeutics, Inc. Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist Vv2735 in Oral Presentation At Obesityweek 2023

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics, Inc. Announces Initiation of Phase 2 Venture Trial of Dual GLP-1/GIP Receptor Agonist Vv2735 in Patients with Obesity

Viking Therapeutics, Inc. to Report Q2, 2023 Results on Jul 26, 2023

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Price target increased by 7.5% to US$31.50

Ligand's Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of Voyage Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis

Price target increased by 12% to US$30.80

Price target increased by 8.1% to US$29.30

Price target increased by 15% to US$21.80

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics, Inc. Provides an Update on Its Clinical Pipeline and Other Corporate Developments

Viking Therapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Viking Therapeutics, Inc. Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

Insufficient new directors

Price target decreased to US$17.33

Viking Therapeutics, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Viking Therapeutics: Playing Second Fiddle To Madrigal

Insufficient new directors

Viking Therapeutics, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Viking Therapeutics Announces FDA Lifted Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth